Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.52 |
| ▸ | PDE4A | P27815 | 4/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931776 | 0.93 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL5203405 | 0.89 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL3072114 | 0.82 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL14484331 | 0.80 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL3069582 | 0.80 | PDE4A (0.55) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3927665 | 0.78 | PDE4B (0.80) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL3918773 | 0.70 | PDE3B (0.68) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL13983258 | 0.70 | HPGD (0.56) | PDE4BSMN1; SMN2ALDH1A1 | |
| SCHEMBL28303332 | 0.69 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL8351887 | 0.69 | MAOB (0.54) | PDE4BPDE4APDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790723-B2 | Thiazole derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1343769-B1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1509506-B1 | PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-7563790-B2 | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7563790-B2 | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7544684-B2 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544684-B2 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544684-B2 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7470687-B2 | Aryl oximes | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470687-B2 | Aryl oximes | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20060270676-A1 | Hydrazono-malonitriles | EGGENWEILER HANS-MICHAEL | 2006-11-30 | — | — | US | disclosed |
| US-7141572-B2 | Hydrazono-malonitriles | MERCK PATENT GESELLSCHAFT (DE) | 2006-11-28 | — | — | US | disclosed |
| EP-1513837-B1 | THIAZOLE DERIVATIVES AS PHOSPHODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1441730-B1 | HYDRAZONO-MALONITRILES | MERCK PATENT GMBH (DE) | 2006-08-09 | — | — | EP | disclosed |
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | MERCK PATENT GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1513837-A1 | THIAZOLE DERIVATIVES AS PHOSPHODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040261190-A1 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
| EP-1441730-A1 | HYDRAZONO-MALONITRILES | Merck Patent GmbH (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004000839-A1 | THIAZOLE DERIVATIVES AS PHOSPHODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003039548-A1 | HYDRAZONO-MALONITRILES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270676-A1 | Hydrazono-malonitriles | ME1, ACHE, ME3 | PDE4B 27/4885PDE4A 12/4885PDE4C 50/4885 |
| US-20040261190-A1 | Hydrazono-malonitriles | ME1, ME3, ACHE | PDE4B 27/4885PDE4A 8/4885PDE4C 55/4885 |
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | PDE3B, PDE4B, PDE4A | PDE4B 2/4885PDE4A 3/4885PDE4C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.